Novo Nordisk diabetes drug effective, no heart risk: FDA review

(Reuters) - Novo Nordisk A/S's closely watched diabetes drug semaglutide is effective and does not cause heart problems, a preliminary review by the U.S. Food and Drug Administration has concluded.